Logo-ps

Submitted: 24 May 2026
Revision: 16 Oct 2026
Accepted: 17 Nov 2026
ePublished: 18 Nov 2026
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Pharm Sci. Inpress.
doi: 10.34172/ps.44057
  Abstract View: 16

Original Article

The Effect of Adjunctive Memantine Added to Betahistine on Symptoms and Quality of Life in Chronic Tinnitus: A Randomized, Single-blind Clinical Trial

Hamed Ghavimi ORCID logo, Azam Maleki ORCID logo, Haleh Shirvani ORCID logo, Mehdi Maghbooli* ORCID logo
*Corresponding Author: Email: m.maghbooli4@gmail.com

Abstract

Background: Tinnitus affects approximately 10–15% of adults and remains a significant medical challenge. Given the role of glutamate excitotoxicity in tinnitus pathophysiology, N-methyl-D-aspartate receptor antagonism represents a promising pharmacological target. This study aimed to evaluate the effect of adjunctive memantine, added to betahistine, on tinnitus severity, insomnia, and quality of life among patients with primary tinnitus. Methods: A single‑blind, randomized controlled trial was conducted on 60 patients with primary tinnitus. All participants received conventional treatment with betahistine (8 mg/day) for 90 days. The intervention group additionally received memantine, titrated up to 20 mg/day, while the control group received a placebo. Outcomes were assessed at baseline and three months post-intervention using the Tinnitus Handicap Inventory, Insomnia Severity Index, and Short Form‑36 Health Survey (SF-36). Data analysis was conducted using chi‑square and independent samples t‑tests with statistical significance set at P < 0.05. Results: At the end of follow-up, the intervention group showed a significant shift toward lower tinnitus severity, with 50% reporting mild and 31% slight tinnitus, while the control group showed no improvement, and 60% remained in the severe category. The between‑group difference in the tinnitus severity distribution was statistically significant (P = 0.001). The intervention group demonstrated significantly greater improvements in health-related quality of life across multiple SF-36 domains and a significant reduction in insomnia severity compared with the control group, with between-group results favoring the memantine-plus-betahistine group (P < 0.05). Conclusion: Adding memantine to betahistine may improve tinnitus-related outcomes compared with betahistine alone. Larger double-blind trials are needed to confirm these findings.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 7

Your browser does not support the canvas element.

PDF Download: 0

Your browser does not support the canvas element.